ArticlePancreas2019
SpHincterotomy for Acute Recurrent Pancreatitis Randomized Trial: Rationale, Methodology, and Potential Implications.
Article in Pancreas, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SpHincterotomy for Acute Recurrent Pancreatitis (SHARP Trial)
STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
Who cites it
10 citing papers in PubMed, 47 citations in OpenAlex.
- Mechanistic insights into pancreatic duct pressure: from basic physiology to translational implications.Current opinion in gastroenterology · 2026Review
- High Confluence of Pancreaticobiliary Ducts with the Frequent Recurrence of Acute Pancreatitis.Internal medicine (Tokyo, Japan) · 2025Article
- Role of endoscopic retrograde cholangiopancreatography in pancreatitis.Journal of the Canadian Association of Gastroenterology · 2025Article
- Endoscopic Management of Benign Pancreaticobiliary Disorders.Journal of clinical medicine · 2025Review
- Idiopathic acute pancreatitis (IAP)-a review of the literature and algorithm proposed for the diagnostic work-up of IAP.Translational gastroenterology and hepatology · 2024Review
- Biliary and pancreatic stents.iGIE : innovation, investigation and insights · 2023Article
- Design and execution of sham-controlled endoscopic trials in acute pancreatitis: Lessons learned from the SHARP trial.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2023Review
- Impact of genetic testing and smoking on the distribution of risk factors in patients with recurrent acute and chronic pancreatitis.Scandinavian journal of gastroenterology · 2022Article
- Secretin-Enhanced MRCP: How and Why-AJR. American journal of roentgenology · 2021Review
- An unusual case of recurrent acute pancreatitis successfully treated via precut papillotomy (with video).Endoscopic ultrasoundArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 16 institutions in 4 countries.
Funding
Abstract
objectivesIn patients with acute recurrent pancreatitis (ARP), pancreas divisum, and no other etiologic factors, endoscopic retrograde cholangiopancreatography (ERCP) with minor papilla endoscopic sphincterotomy (miES) is often performed to enlarge the minor papillary orifice, based on limited data. The aims of this study are to describe the rationale and methodology of a sham-controlled clinical trial designed to test the hypothesis that miES reduces the risk of acute pancreatitis.
methodsThe SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) trial is a multicenter, international, sham-controlled, randomized trial comparing endoscopic ultrasound + ERCP with miES versus endoscopic ultrasound + sham for the management of ARP. A total of 234 consented patients having 2 or more discrete episodes of acute pancreatitis, pancreas divisum confirmed by magnetic resonance cholangiopancreatography, and no other clear etiology for acute pancreatitis will be randomized. Both cohorts will be followed for a minimum of 6 months and a maximum of 48 months.
resultsThe trial is powered to detect a 33% risk reduction of acute pancreatitis frequency.
conclusionsThe SHARP trial will determine whether ERCP with miES benefits patients with idiopathic ARP and pancreas divisum. Trial planning has informed the importance of blinded outcome assessors and long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.